Skip to main
We’re doing some system maintenance
  1. /
  2. Stocks
  3. /
  4. Acceleron Pharma
XLRN

Buy Acceleron Pharma (XLRN) Stock

XLRN
See XLRN stock price and Buy/Sell Acceleron Pharma with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing
XLRN

Acceleron Pharma (XLRN)

We couldn’t load this chart.

Some stock charts might currently not be supported. To try again, please refresh this page.

About Acceleron Pharma (XLRN)

Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ...Read more
Market Cap
$10.94B
1 Year High
$189.99
Volume
1 Year Low
$111.29
Price to Earnings Ratio
Open
Dividend Rate
High
Dividend Yield
Low

Community

People who own or watch XLRN stock

Acceleron Pharma Stock Rating

What analysts recommend for XLRN stock, on a scale from 1(buy) to 5(sell).
Hold3 / 5
BuyHoldSell

Acceleron Pharma Stock Earnings

The value each XLRN share was expected to gain vs. the value that each XLRN share actually gained.
Expected
Actual

Acceleron Pharma Stock News

Frequently Asked Questions (FAQ)

As of Sep 26, 2022, the market cap for XLRN stock is $10.94B

The 52-week high for XLRN stock is $189.99. The current XLRN stock price $0 is 100.00% below its 52-week high

The 52-week low for XLRN stock is $111.29. The current XLRN stock price $0 has increased 100.00% from its 52-week low

No, the XLRN stock does not pay dividends to its shareholders

The target price for XLRN stock is $180 based on the average of what a group of analyst think XLRN stock could be worth at a future date. This is not a prediction by Public.com

Buy Acceleron Pharma (XLRN) Stock

XLRN
See XLRN stock price and Buy/Sell Acceleron Pharma with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing

Community

People who own or watch XLRN stock
  • chis avatar
  • 30acresandamule avatar
  • classifiedclass avatar
  • normanj avatar
  • Nahtanoy avatar
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Market data powered by Xignite.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency execution and custody services are provided by Apex Crypto LLC (NMLS ID 1828849) through a software licensing agreement between Apex Crypto LLC and Public Crypto LLC. Apex Crypto is not a registered broker-dealer or a member of SIPC or FINRA. Cryptocurrencies are not securities and are not FDIC or SIPC insured. Apex Crypto is licensed to engage in virtual currency business activity by the New York State Department of Financial Services. Please ensure that you fully understand the risks involved before trading: Legal Disclosures

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.